Company / Operating Cash Flow
Crinetics Pharmaceuticals, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$377.9M
FY2025
5-year range
-$377.9M / -$88.6M
FY2021-FY2025
Trend
-64.2%
vs FY2024
Sector context
#203 of 216
Health Care
What the data says
Among 216 Health Care companies, Crinetics Pharmaceuticals, Inc. is in the bottom 6% for operating cash flow. Operating Cash Flow has declined for 7 consecutive years, from -$5M in FY2018 to -$378M in FY2025.
Based on SEC 10-K filings.
-$378M in FY2025.
Declined from -$169M to -$378M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 216This company -$377.9M Sector average $658.7M
▼
-157.4% below sector average
Key checks
Key Insights
- Crinetics Pharmaceuticals, Inc.'s operating cash flow has declined for 7 consecutive years.
- In FY2025, operating cash flow decreased 64.2% year-over-year.
- Ranks #203 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$377.9M | -64.2% |
| FY2024 | -$230.2M | -36.5% |
| FY2023 | -$168.6M | -46.3% |
| FY2022 | -$115.2M | -30.0% |
| FY2021 | -$88.6M | -355.3% |
| FY2020 | -$19.5M | -105.3% |
| FY2019 | -$9.5M | -73.4% |
| FY2018 | -$5.5M | +42.3% |
| FY2017 | -$9.5M | -73.4% |
| FY2016 | -$5.5M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026